Supplier
Supplier
Aristo Pharma GmbH
Location unknown
This contract involves establishing active ingredient-based discount agreements in accordance with § 130a Abs. 8 SGB V for specific pharmaceuticals. The agreements will be in effect for a maximum period of 24 months, starting no earlier than April 1, 2026, and ending uniformly on March 31, 2028. Sup
This procurement process is not subject to public procurement law. It is an Open-House procedure aimed at ensuring transparency and broad information dissemination to interested pharmaceutical companies. This announcement is published in the Supplement to the Official Journal of the European Union.